Vimarsana
Biggest News Aggregation in the World

Page 13 - Chuck Kummeth News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Chuck Kummeth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Chuck Kummeth Today - Breaking & Trending Today

Bio-Techne Announces ExoTRU Kidney Transplant Rejection Assay Data Publication - Vimarsana News

Bio-Techne Announces ExoTRU Kidney Transplant Rejection Assay Data Publication

Share this article Share this article MINNEAPOLIS, March 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published preliminary data on its kidney transplant rejection test, ExoTRU™ (Exosome Transplant Rejection Urine), a non-invasive multigene urine-based exosomal mRNA assay. ExoTRU was developed in collaboration with the Azzi laboratory at the Transplantation Research Center at Brigham and Women's Hospital, Harvard Medical School. The ExoTRU test will be the first ever commercially available test capable of d...

Bio-Techne Agrees to Buy Texas Testing Company for Up to $320M - Vimarsana News

Bio-Techne Agrees to Buy Texas Testing Company for Up to $320M

Bio-Techne’s Minneapolis headquarters building Bio-Techne's website Bio-Techne Agrees to Buy Texas Testing Company for Up to $320M Bio-Techne will pay an initial $215 million in cash, with the potential to up the price by $105 million if the company hits “certain future milestones.” Bio-Techne’s Minneapolis headquarters building Bio-Techne's website Minneapolis-based life sciences firm Bio-Techne Corp. on Wednesday said it’s reached a deal to buy Austin, Texas-based Asuragen for up to $320 million. Under the terms of the dea...

Source: tcbmag.com
Bio-Techne to Acquire Asuragen - Vimarsana News

Bio-Techne to Acquire Asuragen

Share this article Share this article MINNEAPOLIS and AUSTIN, Texas, March 3, 2021  /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to acquire Asuragen, Inc. for initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones.  The transaction will be financed through a combination of cash on hand and an existing revolving li...

Bio-Techne Announces Paper Publication In Annals Of Oncology - Vimarsana News

Bio-Techne Announces Paper Publication In Annals Of Oncology

Share this article Share this article MINNEAPOLIS, Feb. 11, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has recently published a paper entitled Exosome-based Liquid Biopsies in Cancer: Opportunities and Challenges (Yu, W et al.), in the highly rated peer-reviewed journal, Annals of Oncology (link). This review paper provides unique insight into liquid biopsies and the field of exosomes in the context of other liquid biopsies such as cfDNA and CTC analysis. The exosome field has gone through a rapid growth phase in ...

Bio-Techne Releases Second Quarter Fiscal 2021 Results - Vimarsana News

Bio-Techne Releases Second Quarter Fiscal 2021 Results

Share this article Share this article MINNEAPOLIS, Feb. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2020. Second Quarter FY2021 Snapshot Second quarter organic revenue increased by 19% (21% reported) to $224.3 million and 15% (16% reported) in the first half of fiscal 2021 to $428.5 million.   GAAP EPS was $1.15 versus $3.02 one year ago primarily relating to a non-recurring gain of approximately $121 million in our ChemoCentryx investment in the second quarter of fiscal 2020. Delivered record a...